Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Sexually Transmitted Diseases

Free Subscription Articles published in Oral Oncol Retrieve available abstracts of 97 articles: HTML format

Single Articles

September 2025
1. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers F, et al
   Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer.
   Oral Oncol. 2025;170:107685.
   PubMed    
   
   
   
2. ZHOU X, Zhang J, Lou Y, Li W, et al
   Immune and HPV landscape in oral multiple primary cancers compared to single primary cancer.
   Oral Oncol. 2025;169:107646.
   PubMed     Abstract available
   
   
   
3. KANIMOZHI K
   Commentary on "Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma".
   Oral Oncol. 2025 Sep 11:107678. doi: 10.1016/j.oraloncology.2025.107678.
   PubMed    
   
   
   
4. LUO L, Lu C, Feng H
   Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
   Oral Oncol. 2025;169:107681.
   PubMed    
   
   
   
5. DUAN Y
   Letter to the Editor: Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
   Oral Oncol. 2025;169:107682.
   PubMed    
   
   
   
6. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
   Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
   Oral Oncol. 2025;169:107654.
   PubMed     Abstract available
   
   
   
7. XU S, Lv Y, He H, Han C, et al
   Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.
   Oral Oncol. 2025;168:107605.
   PubMed     Abstract available
   
   
   August 2025
8. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
   Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
   Oral Oncol. 2025;169:107631.
   PubMed     Abstract available
   
   
   
9. DUAN Y
   Letter to the editor: Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
   Oral Oncol. 2025;169:107638.
   PubMed    
   
   
   
10. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    PubMed     Abstract available
    
    
    
11. SHARFUNNISA SH
    Letter to the Editor: "Refining nutritional support in HPV + oropharyngeal cancer: Insights from a predictive modelling approach".
    Oral Oncol. 2025;168:107574.
    PubMed    
    
    
    
12. MA C, Zeng H
    Comment on: "Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States".
    Oral Oncol. 2025;168:107578.
    PubMed     Abstract available
    
    
    July 2025
13. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    PubMed    
    
    
    
14. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    PubMed     Abstract available
    
    
    
15. KRISHNAN M, Babu S, Rahmathullah A
    Letter to the editor: Toward personalized immunotherapy in OPSCC: Lessons from HPV-driven checkpoint expression.
    Oral Oncol. 2025;168:107547.
    PubMed    
    
    
    
16. SMITH JB, Heiland L, Arnold LD, Simpson MC, et al
    Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
    Oral Oncol. 2025;168:107540.
    PubMed     Abstract available
    
    
    
17. BABU S, Solomon A, Krishnan M
    Revolutionizing HPV-driven cancer surveillance: A commentary on the validation of the HPV-SEQ liquid biopsy platform.
    Oral Oncol. 2025;168:107527.
    PubMed    
    
    
    
18. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    PubMed     Abstract available
    
    
    
19. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    PubMed    
    
    
    
20. SINDYA J, Perumal E
    Commentary on "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;168:107494.
    PubMed    
    
    
    
21. SINGARAVEL V
    Prevalence and genotypic patterns of oral HPV infection in Taiwan-A commentary on the PILLOT study and its relevance to Asian public health strategies.
    Oral Oncol. 2025;167:107479.
    PubMed     Abstract available
    
    
    
22. RAJATHIRAJAN SD
    Commentary on, "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;167:107484.
    PubMed    
    
    
    June 2025
23. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    PubMed     Abstract available
    
    
    
24. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    PubMed     Abstract available
    
    
    
25. ABILAJI S, Narenkumar J
    Letter to the Editor: Human papilloma virus (HPV) associated oral epithelial dysplasia: Emerging evidence, diagnostic challenges, and future directions.
    Oral Oncol. 2025 Jun 23:107434. doi: 10.1016/j.oraloncology.2025.107434.
    PubMed     Abstract available
    
    
    
26. SINGH CHAWLA JP
    Comment on "Circulating miRNAs as diagnostic biomarkers in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC)".
    Oral Oncol. 2025;167:107432.
    PubMed    
    
    
    
27. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available
    
    
    
28. LIU N, Kuang Y, Kuang R
    Comment on the epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107371.
    PubMed    
    
    
    
29. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available
    
    
    May 2025
30. RAJATHIRAJAN SD
    Commentary on, "Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2025;166:107394.
    PubMed    
    
    
    
31. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available
    
    
    
32. YOU J
    Letter to "Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer".
    Oral Oncol. 2025;166:107345.
    PubMed    
    
    
    
33. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available
    
    
    
34. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available
    
    
    
35. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available
    
    
    April 2025
36. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available
    
    
    
37. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available
    
    
    
38. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available
    
    
    
39. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available
    
    
    March 2025
40. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    
    
    
    
41. DSOUZA G, Tewari S, Troy T, Bleyer P, et al
    Oral HPV incidence and risk factors for acquisition.
    Oral Oncol. 2025;163:107249.
    PubMed     Abstract available
    
    
    
42. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available
    
    
    
43. DERMODY SM, Walline H, Bhambhani C, Tewari M, et al
    Addressing knowledge gaps in HPV-related oropharyngeal cancer prevention: A call for action.
    Oral Oncol. 2025;163:107234.
    PubMed    
    
    
    
44. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available
    
    
    
45. THAVARAJ S, Henley-Smith R, Gregson-Williams H, Yogarajah S, et al
    Clinico-pathological characterisation of human papillomavirus-associated oral epithelial dysplasia.
    Oral Oncol. 2025;162:107182.
    PubMed     Abstract available
    
    
    February 2025
46. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available
    
    
    
47. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available
    
    
    January 2025
48. XU S, Qin F, Hu W
    Comment on, "Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy".
    Oral Oncol. 2025;161:107186.
    PubMed    
    
    
    
49. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available
    
    
    
50. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available
    
    
    December 2024
51. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available
    
    
    
52. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available
    
    
    November 2024
53. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    
    
    
    
54. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available
    
    
    
55. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available
    
    
    October 2024
56. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available
    
    
    
57. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available
    
    
    
58. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available
    
    
    
59. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available
    
    
    September 2024
60. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available
    
    
    
61. SANKAR S
    Letter to Editor regarding "Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer".
    Oral Oncol. 2024;159:107020.
    PubMed    
    
    
    August 2024
62. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available
    
    
    
63. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available
    
    
    July 2024
64. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available
    
    
    
65. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available
    
    
    
66. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    
    
    
    
67. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available
    
    
    June 2024
68. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available
    
    
    
69. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    
    
    
    
70. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available
    
    
    
71. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    
    
    
    May 2024
72. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available
    
    
    April 2024
73. WATON A, Chambers A, Fox H, O'Hara J, et al
    Human Papilloma Virus-16 associated primary adenocarcinoma of the tonsil: Report of two cases and literature review.
    Oral Oncol. 2024;151:106766.
    PubMed    
    
    
    March 2024
74. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available
    
    
    
75. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available
    
    
    
76. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available
    
    
    February 2024
77. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available
    
    
    
78. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    PubMed     Abstract available
    
    
    January 2024
79. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    PubMed     Abstract available
    
    
    December 2023
80. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    PubMed     Abstract available
    
    
    November 2023
81. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    PubMed     Abstract available
    
    
    
82. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    PubMed     Abstract available
    
    
    October 2023
83. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    PubMed     Abstract available
    
    
    September 2023
84. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    PubMed     Abstract available
    
    
    
85. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    PubMed     Abstract available
    
    
    
86. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    PubMed    
    
    
    August 2023
87. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    PubMed     Abstract available
    
    
    
88. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    PubMed     Abstract available
    
    
    July 2023
89. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    PubMed     Abstract available
    
    
    
90. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    PubMed     Abstract available
    
    
    
91. DAHLSTROM KR, Sikora AG, Liu Y, Chang CC, et al
    Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
    Oral Oncol. 2023;142:106401.
    PubMed     Abstract available
    
    
    May 2023
92. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    PubMed    
    
    
    April 2023
93. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    PubMed     Abstract available
    
    
    March 2023
94. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    PubMed     Abstract available
    
    
    
95. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    PubMed     Abstract available
    
    
    
96. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    PubMed    
    
    
    
97. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.